Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
bullish
SK Bioscience
Watchlist
SK Bioscience (302440 KS): Dual Engines Led Growth Strategy Is on Track; Solid 1Q25 Performance
Equity Bottom-Up
273 Views
24 Jun 2025 00:30
SK Bioscience initiates global Phase 3 trial of PCV21 vaccine. IDT Biologika shows revenue growth in 1Q25, on track to meet 2025 guidance. 1Q25 base business revenue increased 62% YoY.
What is covered in the Full Insight:
Overview of SK Bioscience's Growth Strategy
Current Performance and Financials
PCV Development Progress
IDT Biologika's Contribution
Near-term Growth Drivers and Market Outlook
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »
Loading
Trending Collections
More »
Japan
Index Rebalance
India
Equity Bottom-Up
Event-Driven
Sell / Short Ideas
Philippines
South Korea
Topix Inclusion
Unpaywalled Insights
Trending Insights
More »
GMO Internet (4784) - Shares Appear Manipulated/Squeezed (Again), but ParentCo MUST SELL
ASX200 Index AdHoc Rebalance Preview: Potential Replacement for Spartan Resources (SPR AU)
Mandatory Cancellation of Existing Treasury Shares: A Historic Stock Market Event in the Making
Merger Arb Mondays (14 Jul) - Shibaura, Topcon, Nissin, OneConnect, Insignia, PointsBet, ENN Energy
BYD (1211 HK): Sales Volume Slowing Down in 2Q25, But Competitors Facing Cash Flow Stress
Top Unpaywalled Insights
More »
Reimagining Venture Capital Through Impact Investing | Chris Maher on Disability Innovation
[IO Technicals 2025/28] Bullish Momentum Intensifies
Mid-Year Themes Review - Part II
De-Dollarisation Debate : Unmasking USD Over-Valuation
US Equities Hit All-Time Highs—but Are Markets Ignoring Growing Risks?
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
SK Bioscience (302440 KS): New Vaccine Trial and ITD Turnaround To Improve Long-Term Outlook
06 Apr 2025
SK Bioscience (302440 KS): Operating Loss Widened in 3Q; What Lies Ahead
26 Oct 2024
SK Bioscience (302440 KS): Acquiring Majority Stake in IDT Biologika- A Step Toward ‘Globalization’
29 Jun 2024
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10
x